Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Liquidia will be responsible for development, regulatory and commercial activities of L606, an inhaled, sustained-release formulation of treprostinil being evaluated for treating PAH and pulmonary hypertension associated with interstitial lung disease, in North America.
Lead Product(s): Treprostinil Sodium
Therapeutic Area: Cardiology/Vascular Diseases Product Name: L606
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Liquidia Corporation
Deal Size: $225.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration June 28, 2023